431
Views
12
CrossRef citations to date
0
Altmetric
Drug Profile

Vilanterol trifenatate for the treatment of COPD

, , &
Pages 719-731 | Received 25 Feb 2016, Accepted 28 Apr 2016, Published online: 25 May 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Timothy E Albertson, Willis S Bowman, Richart W Harper, Regina M Godbout & Susan Murin. (2019) Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1251-1265.
Read now
Nooreen Shaikh, Malcolm Johnson, David A Hall, Kian Fan Chung, John H Riley, Sally Worsley & Pankaj K Bhavsar. (2017) Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1903-1913.
Read now
Nicola A Hanania, Suzanne C. Lareau & Barbara P. Yawn. (2017) Safety of inhaled long-acting anti-muscarinic agents in COPD. Postgraduate Medicine 129:5, pages 500-512.
Read now
Mario Malerba, Alessandro Radaeli, Paolo Montuschi, Kesavan S. Babu & Jaymin B Morjaria. (2017) Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs 26:3, pages 319-329.
Read now
Vicky Chang, Emma L. Gray & Paul S. Thomas. (2016) Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma. Expert Review of Respiratory Medicine 10:10, pages 1069-1078.
Read now

Articles from other publishers (7)

Prahlad Prabhudesai, Bhanu P Singh, Gyanendra Agrawal, Ashok Kumar Singh, Amit Y Jadhav, Saurabh R Patil, Sagar Bhagat, Saiprasad Patil & Hanmant Barkate. (2023) Fluticasone Furoate/Vilanterol Use Trends and Characteristics in Patients With Obstructive Airway Disease: A Real-World Study of 10,374 Patients From India. Cureus.
Crossref
Čižmáriková Ružena, Valentová Jindra & Horáková Renáta. (2020) Chirality of β2-agonists. An overview of pharmacological activity, stereoselective analysis, and synthesis. Open Chemistry 18:1, pages 628-647.
Crossref
Wijdan H. Ramadan, Sarah Al Masri & John Rizk. (2019) Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. The Clinical Respiratory Journal 13:11, pages 663-673.
Crossref
Mario Malerba, Valentina Foci, Filippo Patrucco, Patrizia Pochetti, Matteo Nardin, Corrado Pelaia & Alessandro Radaeli. (2019) Single Inhaler LABA/LAMA for COPD. Frontiers in Pharmacology 10.
Crossref
Agnieszka Sliwka, Milosz Jankowski, Iwona Gross-Sondej, Monika Storman, Roman Nowobilski & Malgorzata M Bala. (2018) Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2018:8.
Crossref
Mario Malerba, Matteo Nardin, Giuseppe Santini, Nadia Mores, Alessandro Radaeli & Paolo Montuschi. (2018) Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. Therapeutic Advances in Respiratory Disease 12, pages 175346661876077.
Crossref
Kesavan Suresh Babu & Jaymin Bhagwanji Morjaria. (2017) Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease 8:4-5, pages 81-91.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.